A phase II study of carboplatin and paclitaxel as first line chemotherapy in elderly patients with advanced non-small cell lung cancer (NSCLC)

Lung Cancer

Volumn 51, Issue 3, 2006, Pages 357-362

  Giorgio, Carmelo Giannitto ^a   Pappalardo, Alessandro ^b   Russo, Antonio ^c   Giuffrida, Dario ^d   Santini, Daniele ^e   Petralia, Giuseppina ^b   Castorina, Sergio ^f   Nunzio, Restuccia ^g   Failla, Giuseppe ^b   Bordonaro, Roberto ^g  

^a Gravina Hospital   (Italy)

^b CCD GB Morgagni   (Italy)

^c UNIVERSITY OF PALERMO   (Italy)

^d Mediterranean Institute of Oncology   (Italy)

^e UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^f UNIVERSITY OF CATANIA   (Italy)

^g UNIVERSITY OF CATANIA   (Italy)

Author keywords

Carboplatin plus paclitaxel; Elderly; Non small cell lung cancer

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ADVANCED CANCER; AGED; AGING; ALOPECIA; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; ATRIOVENTRICULAR BLOCK; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HUMAN; LUNG NON SMALL CELL CANCER; MALAISE; MALE; MYALGIA; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; ITALY; LUNG NEOPLASMS; MALE; PACLITAXEL; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 33144479888     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2005.10.023     Document Type: Article

References (18)

1. S.H. Lundis, T. Murray, S. Bolden, and P.A. Wingo Cancer statistics CA Cancer J Clin 49 1999 8 31
2. J.H. Lewis, M.L. Kilgore, D.P. Goldman, E.L. Trimble, R. Kaplan, and M.J. Montello Partecipation of patients 65 years of age or older in cancer clinical trials J Clin Oncol 21 2003 1383 1389
3. Gridelli C, The ELVIS trial: a phase III study of single-agent vinorelbine as first line treatment in elderly patients with advanced non-small cell lung cancer. Elderly Lung Cancer Vinorelbine Italian Study. Oncologist 2001;1:4-7.
4. G. Frasci, V. Lorusso, N. Panza, P. Comella, G. Nicolella, and A. Bianco Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small cell lung cancer J Clin Oncol 18 2000 2529 2536
5. C. Gridelli, F. Perrone, C. Gallo, S. Cigolari, A. Rossi, and F. Piantedosi Chemotherapy for elderly patients with advanced non-small cell lung cancer: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial J Natl Cancer Inst 95 2003 362 372
6. C.J. Langer, J. Mariola, P. Bernardo, J.W. Kugler, P. Bonomi, and D. Cella Cisplatin-based therapy for elderly patients with advanced non-small cell lung cancer: implication of Eastern Cooperative Oncology Group 5592, a randomized trial J Natl Cancer Inst 94 2002 173 181
7. K. Kelly, S. Giarritta, W. Akerley, P. Hesketh, A. Wozniak, and K. Albain Should older patients receive combination chemotherapy for advanced non-small cell lung cancer (NSCLC)? An analysis of Southwest Oncology Trials 9509 and 9308 Proc Am Soc Clin Oncol 20 2001 239a [Abstract 1313]
8. T.A. Hensing, A.H. Peterman, M.J. Schell, J.H. Lee, and M.A. Socinski The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel Cancer 98 2003 779 788
9. R.C. Lilenbaum, JE. Herndon 2nd, M.A. List, C. Desch, D.M. Watson, and A.A. Miller Single agent versus combination chemotherapy in advanced non-small cell lung cancer: the cancer and leukemia group B (study 9730) J Clin Oncol 23 2005 191 196
10. A.B. Miller, B. Hoogstraten, M. Staquet, and A. Winkler Reporting results of cancer treatment Cancer (Phila.) 47 1981 207 214
11. A.H. Calvert, D.R. Newell, L.A. Gumbrell, S. O'Reilly, M. Burnell, and F.E. Boxall Carboplatin dosage: prospective evaluation of a simple formula based on renal function J Clin Oncol 7 1989 1748 1756
12. D.W. Cockcroft, and M.H. Gault Prediction of creatinine clearance from serum creatinine Nephron 16 1976 31 41
13. M.E. Charlson, P. Pompei, K.L. Ales, and C.R. MacKenzie A new method for of classifying prognostic comorbidity in longitudinal series. Development and validation J Chronics Dis 40 1987 373 383
14. National Cancer Institute: Commo Toxicity Criteria (CTC)., Version 2.0, 1999. http://ctep.cancer.gov/reporting/ctc.html.
15. P.J. Hollen, R.J. Gralla, M.G. Kris, C. Cox, C.P. Belani, and S.M. Grunberg Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies: psycometric assessment of the lung cancer symptom scale Cancer 73 1994 2087 2098
16. 2) plus carboplatin (6 AUC) in advanced non-small-cell lung cancer (NSCLC): a multicenter randomized trial Ann Oncol 11 2000 799 805
17. W.J. Tester, P. Stephenson, C.J. Langer, J.H. Schiller, D.H. Johnson, and B.L. Rapoport ECOG 1599: randomized phase II study of paclitaxel/carboplatin or gemcitabine/cisplatin in performance status(PS) 2 patients with advanced non-small cell lung cancer(NSCLC) Proc Am Soc Clin Oncol 2004 2327 [Abstract 7055]
18. C. Gridelli, M. Aapro, A. Ardizzoni, L. Balducci, F. De Marinis, and K. Kelly Treatment of advanced non-small-cell lung cancer: results of an international expert panel J Clin Oncol 23 2005 3125 3137